Home » Hollis-Eden Rockets on Breast Cancer Drug Data
Hollis-Eden Rockets on Breast Cancer Drug Data
Shares of Hollis-Eden Pharmaceuticals rocketed over 50 percent to $2.51 early Friday after the company released promising early clinical data for its breast cancer drug candidate HE3235.
Market Watch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May